Novel insights in the relationship of gut microbiota and coronary artery diseases
| Autor: | Anny Camelo-Castillo, José Miguel Rivera-Caravaca, Francisco Marín, Cecilia López-García, Esteban Orenes-Piñero, Inmaculada Ramírez-Macías |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
030309 nutrition & dietetics
Firmicutes Trimethylamine N-oxide Coronary Artery Disease Disease Gut flora digestive system Industrial and Manufacturing Engineering Pathogenesis Coronary artery disease 03 medical and health sciences chemistry.chemical_compound 0404 agricultural biotechnology medicine Humans 0303 health sciences Bacteria biology business.industry Probiotics Bacteroidetes 04 agricultural and veterinary sciences General Medicine Atherosclerosis medicine.disease biology.organism_classification 040401 food science Gastrointestinal Microbiome Prebiotics chemistry Immunology Dysbiosis business Food Science |
| Zdroj: | Critical Reviews in Food Science and Nutrition. 62:3738-3750 |
| ISSN: | 1549-7852 1040-8398 |
| Popis: | Atherosclerosis is a chronic, progressive, inflammatory disease in the vasculature and is common in both coronary and peripheral arteries. Human beings harbor a complex and dynamic population of microorganisms defined as the microbiota. Importantly, alterations in the bacterial composition (dysbiosis) and the metabolic compounds produced by these bacteria have been associated with the pathogenesis of many inflammatory diseases and infections. There is also a close relationship between intestinal microbiota and cardiovascular diseases. The aim of this review was to analyze how changes in the gut microbiota and their metabolites might affect coronary artery diseases. The most representative groups of bacteria that make up the intestinal microbiota are altered in coronary artery disease patients, resulting in a decrease in Bacteroidetes and an increase in Firmicutes. In relation to metabolites, trimethylamine-N-oxide plays an important role in atherosclerosis and may act as a cardiovascular risk predictor. In addition, the use of probiotics, prebiotics, diet modulation, and fecal transplantation, which may represent alternative treatments for these diseases, is thoroughly discussed. Finally, the role of lipid-lowering treatments is also analyzed as they may affect and alter the gut microbiota and, conversely, gut microbiota diversity could be associated with resistance or sensitivity to these treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|